Q-omics provides the consensus-scored RNASEK-C17orf49 profile across patient tissues and cancer cell-line models. RNASEK-C17orf49 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNASEK-C17orf49 is differentially expressed in 10, with the highest sampling consensus in STAD. Additionally, RNASEK-C17orf49 RNA expression shows 15,171 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, STAD, and TGCT as cancer lineages where RNASEK-C17orf49 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNASEK-C17orf49 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNASEK-C17orf49 survival associations across molecular data types. RNASEK-C17orf49 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNASEK-C17orf49 RNA expression–survival associations across cancer types. High RNASEK-C17orf49 expression shows unfavorable associations in KIRC, LUAD, PRAD, UCS and READ, but favorable associations in UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNASEK-C17orf49 RNA expression.
This table summarizes RNASEK-C17orf49 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RNASEK-C17orf49. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNASEK-C17orf49 shows lower tumor expression in BRCA and higher tumor expression in STAD, LIHC, KIRC, CHOL and HNSC. The STAD box plot shows higher RNASEK-C17orf49 RNA expression in tumor versus normal tissue (log2 FC = +0.350, t-test p < 0.001).
This table shows molecular features associated with RNASEK-C17orf49 in patient tissues and cancer cell lines. In patient samples, RNASEK-C17orf49 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
